Letter to the editor
Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis

https://doi.org/10.1016/j.jaci.2012.08.029Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

There are more references available in the full text version of this article.

Cited by (17)

  • Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis

    2021, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    Although this allowed for inclusion of a greater number of studies, we were unable to further assess potential risk factors for the use of multiple epinephrine doses, which would have been possible with an IPD meta-analysis. Given the inconsistencies in reported risk factors for multiple epinephrine use,10,11,13-15,21-23 an IPD meta-analysis would help address this evidence gap. Recommendations vary with respect to the number of EAIs that patients at risk of anaphylaxis should be prescribed—both between countries and within a single country in which guidelines from specialist societies may contradict official government advice.5-9

  • Epinephrine in the Management of Anaphylaxis

    2020, Journal of Allergy and Clinical Immunology: In Practice
  • Epinephrine, auto-injectors, and anaphylaxis: Challenges of dose, depth, and device

    2018, Annals of Allergy, Asthma and Immunology
    Citation Excerpt :

    In studies of patients with fatal anaphylaxis, auto-injectors were thought to be of insufficient depth to reach muscle in at least some cases, but the role this may have played in the lethal outcome is unclear.47 In a study of 321 patients presenting to the ED for food allergy or stinging insect allergic reactions, the 69 obese patients were no more likely to receive 2 or more doses of epinephrine than their normal-weight or underweight peers.48 However, most of these subjects were children, in whom the skin-to-bone distances may have been smaller despite obesity.

  • Anaphylaxis: Assessment and management

    2016, Pediatric Allergy: Principles and Practice: Third Edition
  • International consensus on (ICON) anaphylaxis

    2014, World Allergy Organization Journal
    Citation Excerpt :

    The need for prompt epinephrine use to prevent escalation of mediator release in anaphylaxis has been confirmed in a new in vitro model [77]. Use of multiple epinephrine injections does not necessarily correlate with patient obesity [78]. Rates of epinephrine utilization as the initial medication for anaphylaxis in emergency departments are typically low [79]; however, they can be improved significantly with implementation of an anaphylaxis protocol [80, 81].

View all citing articles on Scopus

The study was supported, in part, by an unrestricted gift from Lincoln Medical UK to C.A.C.

Disclosure of potential conflict of interest: C. A. Camargo, Jr has consultancy arrangements with Dey Pharma (Basking Ridge, NJ) and Sanofi Aventis (Bridgewater, NJ). W. Phipatanakul has received one or more grants from or has one or more grants pending with the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.

View full text